Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
Silexion Therapeutics announced positive preclinical immuno-oncology study results for SIL204, their RNAi lead candidate targeting KRAS-mutated pancreatic cancer. SIL204 significantly increased MHC-I expression on cancer cells, potentially enhancing immune system recognition and complementing checkpoint inhibitor therapies. This finding supports SI…